134 related articles for article (PubMed ID: 38000104)
1. Tanshinone IIA normalized hepatocellular carcinoma vessels and enhanced PD-1 inhibitor efficacy by inhibiting ELTD1.
Mao D; Wang H; Guo H; Che X; Chen M; Li X; Liu Y; Huo J; Chen Y
Phytomedicine; 2024 Jan; 123():155191. PubMed ID: 38000104
[TBL] [Abstract][Full Text] [Related]
2. Homologous-magnetic dual-targeted metal-organic framework to improve the Anti-hepatocellular carcinoma efficacy of PD-1 inhibitor.
Guo H; Li X; Mao D; Wang H; Wei L; Qu D; Qin X; Li X; Liu Y; Chen Y
J Nanobiotechnology; 2024 Apr; 22(1):206. PubMed ID: 38658950
[TBL] [Abstract][Full Text] [Related]
3. Tanshinone IIA inhibits metastasis after palliative resection of hepatocellular carcinoma and prolongs survival in part via vascular normalization.
Wang WQ; Liu L; Sun HC; Fu YL; Xu HX; Chai ZT; Zhang QB; Kong LQ; Zhu XD; Lu L; Ren ZG; Tang ZY
J Hematol Oncol; 2012 Nov; 5():69. PubMed ID: 23137165
[TBL] [Abstract][Full Text] [Related]
4. ADGRL4/ELTD1 Expression in Breast Cancer Cells Induces Vascular Normalization and Immune Suppression.
Sheldon H; Bridges E; Silva I; Masiero M; Favara DM; Wang D; Leek R; Snell C; Roxanis I; Kreuzer M; Gileadi U; Buffa FM; Banham A; Harris AL
Mol Cancer Res; 2021 Nov; 19(11):1957-1969. PubMed ID: 34348993
[TBL] [Abstract][Full Text] [Related]
5. ELTD1 deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma.
Huang H; Georganaki M; Conze LL; Laviña B; van Hooren L; Vemuri K; van de Walle T; Ramachandran M; Zhang L; Pontén F; Bergqvist M; Smits A; Betsholtz C; Dejana E; Magnusson PU; He L; Lugano R; Dimberg A
Neuro Oncol; 2022 Mar; 24(3):398-411. PubMed ID: 34347079
[TBL] [Abstract][Full Text] [Related]
6. Enhanced anti-PD-1 therapy in hepatocellular carcinoma by tumor vascular disruption and normalization dependent on combretastatin A4 nanoparticles and DC101.
Bao X; Shen N; Lou Y; Yu H; Wang Y; Liu L; Tang Z; Chen X
Theranostics; 2021; 11(12):5955-5969. PubMed ID: 33897892
[TBL] [Abstract][Full Text] [Related]
7. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy.
Li Q; Han J; Yang Y; Chen Y
Front Immunol; 2022; 13():1070961. PubMed ID: 36601120
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of cytochrome P450 2J2 by tanshinone IIA induces apoptotic cell death in hepatocellular carcinoma HepG2 cells.
Jeon YJ; Kim JS; Hwang GH; Wu Z; Han HJ; Park SH; Chang W; Kim LK; Lee YM; Liu KH; Lee MY
Eur J Pharmacol; 2015 Oct; 764():480-488. PubMed ID: 26209360
[TBL] [Abstract][Full Text] [Related]
9. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
10. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.
Liu Y; Xun Z; Ma K; Liang S; Li X; Zhou S; Sun L; Liu Y; Du Y; Guo X; Cui T; Zhou H; Wang J; Yin D; Song R; Zhang S; Cai W; Meng F; Guo H; Zhang B; Yang D; Bao R; Hu Q; Wang J; Ye Y; Liu L
J Hepatol; 2023 Apr; 78(4):770-782. PubMed ID: 36708811
[TBL] [Abstract][Full Text] [Related]
11. 2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1.
Chen Z; Chen Y; Peng L; Wang X; Tang N
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028694
[TBL] [Abstract][Full Text] [Related]
12. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
[TBL] [Abstract][Full Text] [Related]
13. Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma.
Deng H; Kan A; Lyu N; Mu L; Han Y; Liu L; Zhang Y; Duan Y; Liao S; Li S; Xie Q; Gao T; Li Y; Zhang Z; Zhao M
Liver Cancer; 2020 Jun; 9(3):338-357. PubMed ID: 32647635
[TBL] [Abstract][Full Text] [Related]
14. Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma.
Xiong Z; Chan SL; Zhou J; Vong JSL; Kwong TT; Zeng X; Wu H; Cao J; Tu Y; Feng Y; Yang W; Wong PP; Si-Tou WW; Liu X; Wang J; Tang W; Liang Z; Lu J; Li KM; Low JT; Chan MW; Leung HHW; Chan AWH; To KF; Yip KY; Lo YMD; Sung JJ; Cheng AS
Gut; 2023 Sep; 72(9):1758-1773. PubMed ID: 37019619
[TBL] [Abstract][Full Text] [Related]
15. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.
Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307
[TBL] [Abstract][Full Text] [Related]
16. Targeting the Ang2/Tie2 Axis with Tanshinone IIA Elicits Vascular Normalization in Ischemic Injury and Colon Cancer.
Zou W; Qian C; Zhang S; Wan X; Wei Z; Li X; Wu Y; Chen W; Wang A; Zhao Y; Lu Y
Oxid Med Cell Longev; 2021; 2021():7037786. PubMed ID: 34804370
[TBL] [Abstract][Full Text] [Related]
17. TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity.
Panagi M; Voutouri C; Mpekris F; Papageorgis P; Martin MR; Martin JD; Demetriou P; Pierides C; Polydorou C; Stylianou A; Louca M; Koumas L; Costeas P; Kataoka K; Cabral H; Stylianopoulos T
Theranostics; 2020; 10(4):1910-1922. PubMed ID: 32042344
[TBL] [Abstract][Full Text] [Related]
18. Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFRβ complex in hepatocellular carcinoma.
Yang J; Guo Z; Song M; Pan Q; Zhao J; Huang Y; Han Y; Ouyang D; Yang C; Chen H; Di M; Tang Y; Zhu Q; Wang Q; Li Y; He J; Weng D; Xiang T; Xia J
Front Immunol; 2023; 14():1212577. PubMed ID: 37545530
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma.
Jiang G; Shi L; Zheng X; Zhang X; Wu K; Liu B; Yan P; Liang X; Yu T; Wang Y; Cai X
Aging (Albany NY); 2020 Jun; 12(12):11466-11484. PubMed ID: 32579541
[TBL] [Abstract][Full Text] [Related]
20. Tanshinone II-A inhibits invasion and metastasis of human hepatocellular carcinoma cells in vitro and in vivo.
Yuxian X; Feng T; Ren L; Zhengcai L
Tumori; 2009; 95(6):789-95. PubMed ID: 20210245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
